Aerpio Therapeutics Announces Presentation of Positive Results of AKB-9778 in Patients with Diabetic Retinopathy from TIME-2 Phase 2a Study. AKB ... 2016 11:03 AM Eastern Standard Time.

Breye Therapeutics has begun dosing in its phase 1b/2a trial of oral ... “Danegaptide has the potential to become a valuable oral treatment option for patients with diabetic retinopathy ...

SAN FRANCISCO, Aug. 3, 2023 /PRNewswire/ -- Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases is pleased to announce ...